Sanofi keeps foot on the gas, agreeing to five-year collaboration with MD Anderson
Just four months after scoring its first cancer drug approval in a decade, Sanofi is staying on the oncology offensive.
The French pharma is planning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
